Cancer Incidence and Survival among Adolescents and Young Adults in Korea: An Update for 2016

Purpose This study investigated the incidence and relative survival rates (RSRs) for cancers among adolescents and young adults (AYAs) aged 15-39 years between 1993 and 2016 in Korea. Materials and Methods Data from the Korea Central Cancer Registry were used to calculate percent distributions, age-specific incidence rates, age-standardized incidence rates (ASRs) per million, annual percent changes (APCs), average APCs, and RSRs for cancers diagnosed in AYAs. Results ASR of all cancers among AYAs was 654.5 per million. The largest diagnosed group of cancers was carcinomas (almost 80%). Crude incidence increased with age, from 170.4 per million for those aged 15-19 years to 1,639.8 per million for those aged 35-39 years. ASR increased from 414.8 per million to 820.4 per million, with an APC of 9.0%. The incidence of thyroid carcinoma showed the most rapid increment (APC, 14.0%), followed by non-Hodgkin lymphoma (APC, 13.4%). The 5-year RSR among AYAs significantly improved from 62.1% to 90.8%. Survival improvement in AYAs was higher than that in children but lower than that in older adults (APC, 2.1% vs. 1.9% vs. 3.1%). The most marked survival improvement was found for leukemia and lymphoma. Astrocytoma, rhabdomyosarcoma, and carcinoma of the trachea, bronchus, and lung had a 5-year RSR of < 50%. Conclusion There was an improvement in cancer survivals in AYAs, comparable to that achieved in children. However, survivals in several cancer types do not appear to be improving. Further research focusing on the epidemiology and therapeutic strategies for cancers in AYAs is needed.

Automated summary

This study investigated the incidence and relative survival rates for cancers among adolescents and young adults aged 15-39 in Korea between 1993 and 2016. The ASR of all cancers among AYAs was 654.5 per million, with carcinoma being the most diagnosed type. Thyroid carcinoma and non-Hodgkin lymphoma showed the most rapid increase in incidence. The 5-year RSR among AYAs significantly improved from 62.1% to 90.8%, with the most marked survival improvement found for leukemia and lymphoma. Further research focusing on cancer epidemiology and therapeutic strategies for AYAs is needed.